Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Pretax loss widens to £7.7 million for 2022 from £6.3 million in 2021. Administrative expenses increase to £7.4 million from £6.0 million a year earlier. Research & development expenditure amounts to £4.9 million, up from £3.7 million in 2021. Looking ahead, Destiny Pharma says it will focus on completing the manufacturing scale-up to deliver clinical trial material for the NTCD-M3 clinical programme being run by our partner Sebela. Chief Executive Officer Neil Clark says: ‘Destiny Pharma has made good progress in 2022 and in the first quarter of 2023.’
Current stock price: 30.10 pence, down 1.3% on Thursday afternoon in London
12-month change: down 39%
Copyright 2023 Alliance News Ltd. All Rights Reserved.